Real-Life Dosing With Second-Generation Antipsychotics

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

This is the first of 2 articles addressing methodological issues regarding real-life dosing and switching strategies when treating patients with second-generation antipsychotics.

When faced with nonresponse to an adequate duration of antipsychotic treatment at maximum recommended doses, clinicians have 4 basic options to improve symptomatic and/or functional response: (1) wait for the occurrence of a potentially delayed response; (2) augment with another medication (of the same or a different class); (3) switch to another medication (of the same or a different class); or (4) increase the dose beyond the upper dose range used in U.S. Food and Drug Administration (FDA) approval trials. If sufficient data were available, a fifth option could be to check for the presence of therapeutic antipsychotic drug levels.​

J Clin Psychiatry 2005;66(12):1610-1611